Bart Britten, MD
Family Medicine · Amarillo, TXNPI 1083757504
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 278 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,225 and has fallen 66.0% since, to $417 in 2025.
Across 278 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$750
- Novo Nordisk$389
- GSK$351
- AbbVie$314
- Boehringer Ingelheim$303
- Astellas Pharma US Inc$235
- plus $2K from 35 others
Across 19 payments — averaging $633.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diabetes Care, Inc.$12K
What the payments were for
- Food & beverage$4,517100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,517 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 137 | $112,720 |
| OzempicSemaglutide | 97 | $103,461 |
| MounjaroTirzepatide | 76 | $83,599 |
| JanuviaSitagliptin Phosphate | 74 | $77,248 |
| TradjentaLinagliptin | 76 | $70,261 |
| JardianceEmpagliflozin | 76 | $65,541 |
| EliquisApixaban | 47 | $46,520 |
| MyrbetriqMirabegron | 34 | $21,166 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $19,780 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $18,039 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 20 | $17,901 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,956 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $13,938 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $13,385 |
| Jentadueto XrLinagliptin/Metformin Hcl | 12 | $11,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance, Jentadueto Xr, Synjardy, Synjardy Xr | $303 | $161,292188 claims |
| AstraZenecaFarxiga, Symbicort | $750 | $116,138149 claims |
| MerckJanuvia, Janumet Xr, Janumet | $150 | $108,534114 claims |
| Novo NordiskOzempic | $389 | $103,46197 claims |
| Lilly USA, LLCMounjaro | $126 | $83,59976 claims |
| PfizerEliquis, Premarin | $234 | $49,14260 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $351 | $33,99671 claims |
| Astellas Pharma US IncMyrbetriq | $235 | $21,16634 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $116 | $19,78026 claims |
| AbbVieSynthroid | $314 | $3,21274 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Amarillo
- Sang Tae KimAmarillo$368K
- Ron RankinAmarillo$223K
- Cristiane EnnisAmarillo$128K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.